Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Henna is a botanical extract derived from the leaves of the *Lawsonia inermis* plant. While traditionally used as a cosmetic dye for skin and hair, it is being investigated in clinical oncology as a topical supportive care intervention for hand-foot skin syndrome (HFSS), also known as palmar-plantar erythrodysesthesia (PPE). This condition is a common dose-limiting toxicity associated with chemotherapy agents such as capecitabine and pegylated liposomal doxorubicin. Henna's therapeutic potential is attributed to its active constituent, lawsone (2-hydroxy-1,4-naphthoquinone), which exhibits anti-inflammatory, analgesic, and wound-healing properties. Clinical studies evaluate the application of henna paste to the palms and soles to reduce the severity of erythema, pain, and skin peeling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on henna.